Loss of nuclear envelope phosphatase CTDNEP1 drives aggressive medulloblastoma by triggering MYC amplification and genomic instability
Zaili Luo,Yunfei Liao,Dazhuan Xin,Kalen Berry,Sean Ogurek,Xinran Dong,Hao Li,Jianzhong Yu,Feng Zhang,Ron Han,Chen Dong,Mingyang Xia,Lingli Xu,Yifeng Lin,Chang Ye,Liguo Zhang,Guoying Huang,Wenhao Zhou,Mei Xin,xiaohua hu,Chuntao Zhao,Rohit Rao,Ryuichi Nishinakamura,Jiyang Yu,Marcel Kool,Stefan Pfister,Martine Roussel,William A Weiss,Paul Andreassen,Q. Richard Lu
DOI: https://doi.org/10.21203/rs.3.rs-421098/v1
2021-01-01
Abstract:Abstract MYC-driven medulloblastomas are highly aggressive childhood brain tumors, however, the genetic events triggering MYC amplification and malignant transformation remain elusive. Here we report that mutations in CTDNEP1, a CTD nuclear-envelope-phosphatase, are the most significantly enriched recurrent alterations in MYC-driven medulloblastomas, and define high-risk subsets with poorer prognosis. CTDNEP1 ablation transforms murine cerebellar progenitors into MYC-amplified medulloblastomas, resembling their human counterparts. CTDNEP1 deficiency stabilizes MYC protein by elevating MYC serine-62 phosphorylation, and triggers genomic instability with eventual MYC amplification and p53 loss. Further, phosphoproteomics reveals that CTDNEP1 post-translationally modulates the activities of key regulators for proper chromosome segregation and mitotic checkpoints including topoisomerase TOP2A and checkpoint kinase CHEK1. Co-targeting CHEK1 and MYC activities synergistically inhibits CTDNEP1-deficient MYC-amplified tumor growth and prolongs animal survival. Together, our studies identify CTDNEP1 acting as a tumor suppressor in highly aggressive medulloblastomas by maintaining homeostatic MYC levels and genomic stability, highlighting a CTDNEP1-dependent therapeutic vulnerability.